1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Proton Pump

Proton Pump

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (39):

Cat. No. Product Name Effect Purity
  • HY-100558
    Bafilomycin A1 Inhibitor 99.43%
    Bafilomycin A1, a macrolide antibiotic isolated from the Streptomyces species, is a specific inhibitor of vacuolar-type H+ ATPase (V-ATPase). Bafilomycin A1 inhibits autophagy and induces apoptosis.
  • HY-B0113
    Omeprazole Inhibitor
    Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.
  • HY-17507A
    Pantoprazole sodium Inhibitor 99.89%
    Pantoprazole sodium (BY1023 sodium; SKF96022 sodium) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
  • HY-128892
    EN6 Activator 99.58%
    EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase). EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner.
  • HY-B0572
    Zinc Pyrithione Inhibitor >98.0%
    Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
  • HY-109079A
    Abeprazan hydrochloride Inhibitor
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.
  • HY-109079
    Abeprazan Inhibitor
    Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.
  • HY-118283
    5-Hydroxylansoprazole Inhibitor
    5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases.
  • HY-100007
    Vonoprazan Inhibitor 99.33%
    Vonoprazan (TAK-438 free base) is an orally active potassium-competitive acid blocker which inhibits H+, K+-ATPase activity with an IC50 of 19 nM.
  • HY-101664
    Ilaprazole Inhibitor >98.0%
    Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
  • HY-B0656A
    Rabeprazole sodium Inhibitor 99.17%
    Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.
  • HY-13662
    Lansoprazole Inhibitor >98.0%
    Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid.
  • HY-15295
    Vonoprazan Fumarate Inhibitor 99.97%
    Vonoprazan Fumarate (TAK-438) is an orally active potassium-competitive acid blocker which inhibits H+, K+-ATPase activity with an IC50 of 19 nM.
  • HY-13662B
    (R)-Lansoprazole Inhibitor
    (R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.
  • HY-100414
    Soraprazan Inhibitor 99.02%
    Soraprazan is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase.
  • HY-17022
    Esomeprazole Magnesium trihydrate Inhibitor
    Esomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells.
  • HY-B1446
    Esomeprazole magnesium Inhibitor 98.49%
    Esomeprazole magnesium is an inhibitor of H+, K+-ATPase, effectively used in the research of upper intestinal disorder.
  • HY-N1724
    Concanamycin A Inhibitor >98.0%
    Concanamycin A (Antibiotic X 4357B) is a macrolide antibiotic and a specific vacuolar type H+-ATPase (V-ATPase) inhibitor.
  • HY-101427
    Bamaquimast Inhibitor >98.0%
    Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138.
  • HY-100412
    Linaprazan Inhibitor 98.89%
    Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.